Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2021

Open Access 01-12-2021 | Arterial Diseases | Research

Risk stratification and mortality prediction in octo- and nonagenarians with peripheral artery disease: a retrospective analysis

Authors: Christos Rammos, Aristotelis Kontogiannis, Amir A. Mahabadi, Martin Steinmetz, Daniel Messiha, Julia Lortz, Tienush Rassaf

Published in: BMC Cardiovascular Disorders | Issue 1/2021

Login to get access

Abstract

Objectives

Among changes in demographics, aging is the most relevant cardiovascular risk factor. The prevalence of peripheral artery disease (PAD) is high in elderly patients and is associated with a worse prognosis. Despite optimal treatments, mortality in the high-risk population of octo- and nonagenarians with PAD remains excessive, and predictive factors need to be identified. The objective of this study was to investigate predictors of mortality in octo- and nonagenarians with PAD.

Methods

Cases of treated octo- and nonagenarians, including the clinical characteristics and markers of myocardial injury and heart failure, were studied retrospectively with respect to all-cause mortality. Hazard ratios [HR] were calculated and survival was analyzed by Kaplan-Meyer curves and receiver operating characteristic curved were assessed for troponin-ultra and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels and chronic limb-threatening ischemia (CLTI).

Results

A total of 123 octo- and nonagenarians admitted for PAD were eligible. The troponin level was the major predictor of all-cause mortality (HR: 4.6, 95% confidence interval [CI]: 1.4–15.3), followed by the NT-proBNP level (HR: 3.9, 95% CI 1.8–8.8) and CLTI (HR: 3.1, 95% CI 1.6–5.9). Multivariate regression revealed that each increment of 1 standard deviation in log troponin and log NT-proBNP was associated with a 2.7-fold (95% CI 1.8–4.1) and a 1.9-fold (95% CI 1.2–2.9) increased risk of all-cause death. Receiver operating characteristic curve analysis using a combination of all predictors yielded an improved area under the curve of 0.888. In a control group of an equal number of younger individuals, only NT-proBNP (HR: 4.2, 95% CI 1.2–14.1) and CLTI (HR: 6.1, 95% CI 1.6–23.4) were predictive of mortality.

Conclusion

Our study demonstrates that cardiovascular biomarkers and CLTI are the primary predictors of increased mortality in elderly PAD patients. Further risk stratification through biomarkers in this high-risk population of octo- and nonagenarians with PAD is necessary.
Appendix
Available only for authorised users
Literature
1.
go back to reference United Nations, Department of Economic and Social Affairs, Population Division. World Population Ageing 2013;ST/ESA/SER.A/348. United Nations, Department of Economic and Social Affairs, Population Division. World Population Ageing 2013;ST/ESA/SER.A/348.
2.
go back to reference Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–44.CrossRef Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933–44.CrossRef
3.
go back to reference Paneni F, Diaz Canestro C, Libby P, et al. The aging cardiovascular system: understanding it at the cellular and clinical levels. J Am Coll Cardiol. 2017;69:1952–67.CrossRef Paneni F, Diaz Canestro C, Libby P, et al. The aging cardiovascular system: understanding it at the cellular and clinical levels. J Am Coll Cardiol. 2017;69:1952–67.CrossRef
4.
go back to reference Rammos C, Hendgen-Cotta UB, Deenen R, et al. Age-related vascular gene expression profiling in mice. Mech Ageing Dev. 2014;135:15–23.CrossRef Rammos C, Hendgen-Cotta UB, Deenen R, et al. Age-related vascular gene expression profiling in mice. Mech Ageing Dev. 2014;135:15–23.CrossRef
5.
go back to reference Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–292.CrossRef Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–292.CrossRef
6.
go back to reference Piepoli MF, Hoes AW, Agewall S, et al. European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–81.CrossRef Piepoli MF, Hoes AW, Agewall S, et al. European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–81.CrossRef
7.
go back to reference Kullo IJ, Rooke TW. Clinical practice. Peripheral artery disease. N Engl J Med. 2016;374:861–371.CrossRef Kullo IJ, Rooke TW. Clinical practice. Peripheral artery disease. N Engl J Med. 2016;374:861–371.CrossRef
8.
go back to reference Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol. 2011;8:13–28.CrossRef Fleg JL, Aronow WS, Frishman WH. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol. 2011;8:13–28.CrossRef
9.
go back to reference Shanmugam VB, Harper R, Meredith I, et al. An overview of PCI in the very elderly. J Geriatr Cardiol. 2015;12:174–84.PubMedPubMedCentral Shanmugam VB, Harper R, Meredith I, et al. An overview of PCI in the very elderly. J Geriatr Cardiol. 2015;12:174–84.PubMedPubMedCentral
10.
go back to reference Bromage DI, Jones DA, Rathod KS, et al. Outcome of 1051 octogenarian patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: observational cohort from the London Heart Attack Group. J Am Heart Assoc. 2016;5:e003027.CrossRef Bromage DI, Jones DA, Rathod KS, et al. Outcome of 1051 octogenarian patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: observational cohort from the London Heart Attack Group. J Am Heart Assoc. 2016;5:e003027.CrossRef
11.
go back to reference Cea Soriano L, Fowkes FGR, Johansson S, et al. Cardiovascular outcomes for patients with symptomatic peripheral artery disease: a cohort study in The Health Improvement Network (THIN) in the UK. Eur J Prev Cardiol. 2017;24:1927–37.CrossRef Cea Soriano L, Fowkes FGR, Johansson S, et al. Cardiovascular outcomes for patients with symptomatic peripheral artery disease: a cohort study in The Health Improvement Network (THIN) in the UK. Eur J Prev Cardiol. 2017;24:1927–37.CrossRef
12.
go back to reference Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2017;39:763–816.CrossRef Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2017;39:763–816.CrossRef
13.
go back to reference Lortz J, Halfmann L, Burghardt A, et al. Rapid and automated risk stratification by determination of the aortic stiffness in healthy subjects and subjects with cardiovascular disease. PLoS ONE. 2019;14:e0216538.CrossRef Lortz J, Halfmann L, Burghardt A, et al. Rapid and automated risk stratification by determination of the aortic stiffness in healthy subjects and subjects with cardiovascular disease. PLoS ONE. 2019;14:e0216538.CrossRef
14.
go back to reference Rammos C, Radecke T, Lortz J et al. Guidelines adherence or chronic total occlusion recanalization of the superficial femoral artery with a stentless approach: the next frontier? SAGE Open Med Case Rep. 2019;7:2050313X18823445. Rammos C, Radecke T, Lortz J et al. Guidelines adherence or chronic total occlusion recanalization of the superficial femoral artery with a stentless approach: the next frontier? SAGE Open Med Case Rep. 2019;7:2050313X18823445.
15.
go back to reference Ibrahim NE, Burnett JC Jr, Butler J, et al. Natriuretic peptides as inclusion criteria in clinical trials: a JACC: heart failure position paper. JACC Heart Fail. 2020;8:347–58.CrossRef Ibrahim NE, Burnett JC Jr, Butler J, et al. Natriuretic peptides as inclusion criteria in clinical trials: a JACC: heart failure position paper. JACC Heart Fail. 2020;8:347–58.CrossRef
16.
go back to reference Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a “set up” for vascular disease. Circulation. 2003;107:139–46.CrossRef Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a “set up” for vascular disease. Circulation. 2003;107:139–46.CrossRef
17.
go back to reference Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation. 2003;107:346–54.CrossRef Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation. 2003;107:346–54.CrossRef
18.
go back to reference Aronow WS, Ahn C, Mercando AD, et al. Prognostic significance of silent ischemia in elderly patients with peripheral arterial disease with and without previous myocardial infarction. Am J Cardiol. 1992;69:137–9.CrossRef Aronow WS, Ahn C, Mercando AD, et al. Prognostic significance of silent ischemia in elderly patients with peripheral arterial disease with and without previous myocardial infarction. Am J Cardiol. 1992;69:137–9.CrossRef
19.
go back to reference Aronow WS. Management of peripheral arterial disease of the lower extremities in elderly patients. J Gerontol A Biol Sci Med Sci. 2004;59:172–7.CrossRef Aronow WS. Management of peripheral arterial disease of the lower extremities in elderly patients. J Gerontol A Biol Sci Med Sci. 2004;59:172–7.CrossRef
20.
go back to reference Siontis GCM, Overtchouk P, Cahill TJ, et al. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J. 2019;40:3143–53.CrossRef Siontis GCM, Overtchouk P, Cahill TJ, et al. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J. 2019;40:3143–53.CrossRef
21.
go back to reference Bell SP, Saraf A. Risk stratification in very old adults: how to best gauge risk as the basis of management choices for patients aged over 80. Prog Cardiovasc Dis. 2014;57:197–203.CrossRef Bell SP, Saraf A. Risk stratification in very old adults: how to best gauge risk as the basis of management choices for patients aged over 80. Prog Cardiovasc Dis. 2014;57:197–203.CrossRef
22.
go back to reference Wang TY, Gutierrez A, Peterson ED. Percutaneous coronary intervention in the elderly. Nat Rev Cardiol. 2011;8:79–90.CrossRef Wang TY, Gutierrez A, Peterson ED. Percutaneous coronary intervention in the elderly. Nat Rev Cardiol. 2011;8:79–90.CrossRef
23.
go back to reference Morici N, Savonitto S, Ferri LA, et al. Outcomes of elderly patients with ST-elevation or non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention. Am J Med. 2019;132:209–16.CrossRef Morici N, Savonitto S, Ferri LA, et al. Outcomes of elderly patients with ST-elevation or non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention. Am J Med. 2019;132:209–16.CrossRef
24.
go back to reference Dick P, Barth B, Mlekusch W, et al. Complications after peripheral vascular interventions in octogenarians. J Endovasc Ther. 2008;15:383–9.CrossRef Dick P, Barth B, Mlekusch W, et al. Complications after peripheral vascular interventions in octogenarians. J Endovasc Ther. 2008;15:383–9.CrossRef
25.
go back to reference Plaisance BR, Munir K, Share DA, et al. Safety of contemporary percutaneous peripheral arterial interventions in the elderly insights from the BMC2 PVI (Blue Cross Blue Shield of Michigan Cardiovascular Consortium Peripheral Vascular Intervention) registry. JACC Cardiovasc Interv. 2011;4:694–701.CrossRef Plaisance BR, Munir K, Share DA, et al. Safety of contemporary percutaneous peripheral arterial interventions in the elderly insights from the BMC2 PVI (Blue Cross Blue Shield of Michigan Cardiovascular Consortium Peripheral Vascular Intervention) registry. JACC Cardiovasc Interv. 2011;4:694–701.CrossRef
26.
go back to reference Matsushita K, Kwak L, Yang C, et al. High-sensitivity cardiac troponin and natriuretic peptide with risk of lower-extremity peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) Study. Eur Heart J. 2018;39:2412–9.CrossRef Matsushita K, Kwak L, Yang C, et al. High-sensitivity cardiac troponin and natriuretic peptide with risk of lower-extremity peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) Study. Eur Heart J. 2018;39:2412–9.CrossRef
27.
go back to reference Ikonomidis I, Aboyans V, Blacher J, et al. The role of ventricular-arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases, European Association of Cardiovascular Imaging, and Heart Failure Association. Eur J Heart Fail. 2019;21:402–24.CrossRef Ikonomidis I, Aboyans V, Blacher J, et al. The role of ventricular-arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases, European Association of Cardiovascular Imaging, and Heart Failure Association. Eur J Heart Fail. 2019;21:402–24.CrossRef
28.
go back to reference Ikonomidis I, Katsanos S, Triantafyllidi H, et al. Pulse wave velocity to global longitudinal strain ratio in hypertension. Eur J Clin Invest. 2019;49:e13049.CrossRef Ikonomidis I, Katsanos S, Triantafyllidi H, et al. Pulse wave velocity to global longitudinal strain ratio in hypertension. Eur J Clin Invest. 2019;49:e13049.CrossRef
29.
go back to reference Mueller T, Hinterreiter F, Luft C, et al. Mortality rates and mortality predictors in patients with symptomatic peripheral artery disease stratified according to age and diabetes. J Vasc Surg. 2014;59:1291–9.CrossRef Mueller T, Hinterreiter F, Luft C, et al. Mortality rates and mortality predictors in patients with symptomatic peripheral artery disease stratified according to age and diabetes. J Vasc Surg. 2014;59:1291–9.CrossRef
30.
go back to reference Linnemann B, Sutter T, Herrmann E, et al. Elevated cardiac troponin T is associated with higher mortality and amputation rates in patients with peripheral arterial disease. J Am Coll Cardiol. 2014;63:1529–38.CrossRef Linnemann B, Sutter T, Herrmann E, et al. Elevated cardiac troponin T is associated with higher mortality and amputation rates in patients with peripheral arterial disease. J Am Coll Cardiol. 2014;63:1529–38.CrossRef
31.
go back to reference Linnemann B, Sutter T, Sixt S, et al. Elevated cardiac troponin T contributes to prediction of worse in-hospital outcomes after endovascular therapy for acute limb ischemia. J Vasc Surg. 2012;55:721–9.CrossRef Linnemann B, Sutter T, Sixt S, et al. Elevated cardiac troponin T contributes to prediction of worse in-hospital outcomes after endovascular therapy for acute limb ischemia. J Vasc Surg. 2012;55:721–9.CrossRef
32.
go back to reference Sarveswaran J, Ikponmwosa A, Asthana S, et al. Should cardiac troponins be used as a risk stratification tool for patients with chronic critical limb ischaemia? Eur J Vasc Endovasc Surg. 2007;33:703–7.CrossRef Sarveswaran J, Ikponmwosa A, Asthana S, et al. Should cardiac troponins be used as a risk stratification tool for patients with chronic critical limb ischaemia? Eur J Vasc Endovasc Surg. 2007;33:703–7.CrossRef
33.
go back to reference Armstrong EJ, Chen DC, Westin GG, et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc. 2014;3:e000697.CrossRef Armstrong EJ, Chen DC, Westin GG, et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc. 2014;3:e000697.CrossRef
34.
go back to reference Khavandi A, Khavandi K, Greenstein A, et al. n-3 Polyunsaturated fatty acids are still underappreciated and underused post myocardial infarction. Heart. 2009;95:540–1.CrossRef Khavandi A, Khavandi K, Greenstein A, et al. n-3 Polyunsaturated fatty acids are still underappreciated and underused post myocardial infarction. Heart. 2009;95:540–1.CrossRef
35.
go back to reference Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–24.CrossRef Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–24.CrossRef
36.
go back to reference Subherwal S, Patel MR, Kober L, et al. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation. 2012;126:1345–54.CrossRef Subherwal S, Patel MR, Kober L, et al. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation. 2012;126:1345–54.CrossRef
37.
go back to reference Hoeks SE, Scholte op Reimer WJ, van Gestel YR, et al. Medication underuse during long-term follow-up in patients with peripheral arterial disease. Circ Cardiovasc Qual Outcomes. 2009;2:338–43.CrossRef Hoeks SE, Scholte op Reimer WJ, van Gestel YR, et al. Medication underuse during long-term follow-up in patients with peripheral arterial disease. Circ Cardiovasc Qual Outcomes. 2009;2:338–43.CrossRef
38.
go back to reference Phan DQ, Duan L, Lam B, et al. Statin adherence and mortality in patients aged 80 years and older after acute myocardial infarction. J Am Geriatr Soc. 2019;67:2045–9.CrossRef Phan DQ, Duan L, Lam B, et al. Statin adherence and mortality in patients aged 80 years and older after acute myocardial infarction. J Am Geriatr Soc. 2019;67:2045–9.CrossRef
39.
go back to reference Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763–816.CrossRef Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763–816.CrossRef
40.
go back to reference Amrock SM, Abraham CZ, Jung E, et al. Risk factors for mortality among individuals with peripheral arterial disease. Am J Cardiol. 2017;120:862–7.CrossRef Amrock SM, Abraham CZ, Jung E, et al. Risk factors for mortality among individuals with peripheral arterial disease. Am J Cardiol. 2017;120:862–7.CrossRef
Metadata
Title
Risk stratification and mortality prediction in octo- and nonagenarians with peripheral artery disease: a retrospective analysis
Authors
Christos Rammos
Aristotelis Kontogiannis
Amir A. Mahabadi
Martin Steinmetz
Daniel Messiha
Julia Lortz
Tienush Rassaf
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2021
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-021-02177-1

Other articles of this Issue 1/2021

BMC Cardiovascular Disorders 1/2021 Go to the issue